Filing Details

Accession Number:
0001562180-22-002162
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-02 21:10:56
Reporting Period:
2022-02-28
Accepted Time:
2022-03-02 21:10:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA Pharmaceutical Preparations (2834) 208756903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776024 Dell Faulkingham C/O Akebia Therapeutics, Inc.
245 First Street
Cambridge MA 02142
Svp, Cco No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-02-28 6,479 $2.15 130,546 No 4 S Direct
Common Stock Acquisiton 2022-02-28 50,000 $0.00 180,546 No 4 A Direct
Common Stock Disposition 2022-03-01 5,748 $2.17 174,798 No 4 S Direct
Common Stock Disposition 2022-03-01 957 $2.17 173,841 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to buy) Acquisiton 2022-02-28 200,000 $0.00 200,000 $2.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
200,000 2032-02-28 No 4 A Direct
Footnotes
  1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
  2. The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
  3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
  4. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
  5. The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.